Thank you
@BrettSperryMD
and
@maz_hanna
for putting on such a wonderful and educational conference! Can't wait to tune in next weekend! Some takeaways on the nuances of management:
International Congress on ATTR Amyloidosis (
#ICAA21
) is starting in 10 minutes!
@medscapeLIVE
See the agenda and register here:
First session below
0
4
21
1
0
10
Replies
✨Diflunisal may have a role in hATTR gene carriers without overt disease or in patients with polyneuropathy and MSK symptoms in combo with silencer therapy
✨Reasonable from device therapy standpoint in symptomatic patients to increase base HR in those with PPM given fixed SV
1
0
3
✨Goals of therapy are different in ATTR given different pathophys. Don't start GDMT in ATTR with HFrEF thinking it will lead to improvement however certain therapies can be utilized for specific targeted indications
1
0
3
✨Spiro+diuretic for volume control. BB can be helpful for rate control. ACEi/ARB reasonable in hypertensive patients
✨Remember to manage expectations when starting stabilizer. Let patient know that they will likely not feel better but that therapy can slow progression
1
0
3
✨In the age of stabilizer/silencer therapies hard to justify need for heart/liver in hATTR as was previously the case
✨Post heart transplant therapy is a data-free zone but if lifestyle limiting neuropathy reasonable to use silencer therapy
1
0
5
0
0
7